Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-IRDye800CW in locally advanced rectal cancer
NCT04638036Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW in rectal cancer, sponsored by University Medical Center Groningen. Primary endpoints: Safety of molecular fluorescence endoscopy using Cetuximab-800CW at 3 months, Safety of molecular fluorescence-guided surgery using Cetuximab-800CW at 3 months and 2 more. Started Nov 2020; status: completed.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04638036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638036.